These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 27701176)
1. The Protective Effect of Febuxostat on Chronic Tacrolimus-Induced Nephrotoxicity in Rats. Kim HS; Lim SW; Jin L; Jin J; Chung BH; Yang CW Nephron; 2017; 135(1):61-71. PubMed ID: 27701176 [TBL] [Abstract][Full Text] [Related]
2. Cilastatin protects against tacrolimus-induced nephrotoxicity via anti-oxidative and anti-apoptotic properties. Luo K; Lim SW; Jin J; Jin L; Gil HW; Im DS; Hwang HS; Yang CW BMC Nephrol; 2019 Jun; 20(1):221. PubMed ID: 31200653 [TBL] [Abstract][Full Text] [Related]
3. Febuxostat ameliorates diabetic renal injury in a streptozotocin-induced diabetic rat model. Lee HJ; Jeong KH; Kim YG; Moon JY; Lee SH; Ihm CG; Sung JY; Lee TW Am J Nephrol; 2014; 40(1):56-63. PubMed ID: 25034030 [TBL] [Abstract][Full Text] [Related]
4. Cardio-renal protective effect of the xanthine oxidase inhibitor febuxostat in the 5/6 nephrectomy model with hyperuricemia. Omizo H; Tamura Y; Morimoto C; Ueno M; Hayama Y; Kuribayashi-Okuma E; Uchida S; Shibata S Sci Rep; 2020 Jun; 10(1):9326. PubMed ID: 32518351 [TBL] [Abstract][Full Text] [Related]
5. Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. Sánchez-Lozada LG; Tapia E; Soto V; Avila-Casado C; Franco M; Wessale JL; Zhao L; Johnson RJ Nephron Physiol; 2008; 108(4):p69-78. PubMed ID: 18434753 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients. Sofue T; Inui M; Hara T; Nishijima Y; Moriwaki K; Hayashida Y; Ueda N; Nishiyama A; Kakehi Y; Kohno M Drug Des Devel Ther; 2014; 8():245-53. PubMed ID: 24600205 [TBL] [Abstract][Full Text] [Related]
8. Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Sánchez-Lozada LG; Tapia E; Soto V; Avila-Casado C; Franco M; Zhao L; Johnson RJ Nephrol Dial Transplant; 2008 Apr; 23(4):1179-85. PubMed ID: 18048425 [TBL] [Abstract][Full Text] [Related]
9. Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial. Tanaka A; Taguchi I; Teragawa H; Ishizaka N; Kanzaki Y; Tomiyama H; Sata M; Sezai A; Eguchi K; Kato T; Toyoda S; Ishibashi R; Kario K; Ishizu T; Ueda S; Maemura K; Higashi Y; Yamada H; Ohishi M; Yokote K; Murohara T; Oyama JI; Node K; PLoS Med; 2020 Apr; 17(4):e1003095. PubMed ID: 32320401 [TBL] [Abstract][Full Text] [Related]
10. Time to target uric acid to retard CKD progression. Kumagai T; Ota T; Tamura Y; Chang WX; Shibata S; Uchida S Clin Exp Nephrol; 2017 Apr; 21(2):182-192. PubMed ID: 27339448 [TBL] [Abstract][Full Text] [Related]
11. Green tea polyphenols decreases uric acid level through xanthine oxidase and renal urate transporters in hyperuricemic mice. Chen G; Tan ML; Li KK; Leung PC; Ko CH J Ethnopharmacol; 2015 Dec; 175():14-20. PubMed ID: 26344851 [TBL] [Abstract][Full Text] [Related]
12. The molecular insight into the antihyperuricemic and renoprotective effect of Shuang Qi gout capsule in mice. Kodithuwakku ND; Feng YD; Zhang YY; Pan M; Fang WR; Li YM J Ethnopharmacol; 2015 Apr; 163():278-89. PubMed ID: 25614106 [TBL] [Abstract][Full Text] [Related]
13. Effects of Febuxostat on Oxidative Stress. Fukui T; Maruyama M; Yamauchi K; Yoshitaka S; Yasuda T; Abe Y Clin Ther; 2015 Jul; 37(7):1396-401. PubMed ID: 25913922 [TBL] [Abstract][Full Text] [Related]
14. Mangiferin Inhibits Renal Urate Reabsorption by Modulating Urate Transporters in Experimental Hyperuricemia. Yang H; Gao L; Niu Y; Zhou Y; Lin H; Jiang J; Kong X; Liu X; Li L Biol Pharm Bull; 2015; 38(10):1591-8. PubMed ID: 26228630 [TBL] [Abstract][Full Text] [Related]
15. Linagliptin ameliorates tacrolimus-induced renal injury: role of Nrf2/HO-1 and HIF-1α/CTGF/PAI-1. Nady ME; El-Raouf OMA; El-Sayed EM Mol Biol Rep; 2024 May; 51(1):608. PubMed ID: 38704766 [TBL] [Abstract][Full Text] [Related]
16. Time to Target Uric Acid to Retard Chronic Kidney Disease Progression. Uchida S; Kumagai T; Chang WX; Tamura Y; Shibata S Contrib Nephrol; 2018; 192():56-68. PubMed ID: 29393121 [TBL] [Abstract][Full Text] [Related]
17. [Effect of total saponin of Dioscorea on chronic hyperuricemia and expression of URAT1 in rats]. Chen GL; Zhu LR; Na S; Li L Zhongguo Zhong Yao Za Zhi; 2013 Jul; 38(14):2348-53. PubMed ID: 24199570 [TBL] [Abstract][Full Text] [Related]
18. Combined treatment of tacrolimus and everolimus increases oxidative stress by pharmacological interactions. Piao SG; Lim SW; Doh KC; Jin L; Heo SB; Zheng YF; Bae SK; Chung BH; Li C; Yang CW Transplantation; 2014 Jul; 98(1):22-8. PubMed ID: 24825522 [TBL] [Abstract][Full Text] [Related]
19. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model. Nakatsu Y; Seno Y; Kushiyama A; Sakoda H; Fujishiro M; Katasako A; Mori K; Matsunaga Y; Fukushima T; Kanaoka R; Yamamotoya T; Kamata H; Asano T Am J Physiol Gastrointest Liver Physiol; 2015 Jul; 309(1):G42-51. PubMed ID: 25999428 [TBL] [Abstract][Full Text] [Related]
20. Ameliorative effects of sildenafil and/or febuxostat on doxorubicin-induced nephrotoxicity in rats. Khames A; Khalaf MM; Gad AM; Abd El-Raouf OM Eur J Pharmacol; 2017 Jun; 805():118-124. PubMed ID: 28257823 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]